Editing
Evaluation and Management of Erectile Dysfunction
(section)
Jump to navigation
Jump to search
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Intraurethral (IU) alprostadil === * '''Relies on the absorption of the medication''' into the surrounding corpus spongiosum, with passage via small vascular channels '''into the''' '''corpora cavernosa''', the main erectile bodies * Known as MUSE (Medicated Urethral System for Erection) * Uses a suppository inserted into the urethral opening that '''dispenses a semisolid pellet''' (1x3mm) '''of alprostadil''' (125, 250, 500, and 1000mcg dosages) '''into the distal urethra''' (3cm from the external urethral meatus) * '''Inferior efficacy compared to PDE5 inhibitors and ICI''' * '''Treatment option when:''' ** '''Patient prefers to avoid oral medication and avoid needles required for ICI medications''' ** '''PDE5i are contraindicated''' ** The main indications are patients who are non-responsive to PDE5 inhibitors resulting from damage of the autonomic penile nerve supply (e.g., radical prostatectomy, cystectomy, and trauma) or those who wish to use the therapy in combination with PDE5 inhibitors. * '''The most common adverse events are genital pain, minor urethral trauma/bleeding, urethral pain or burning, and dizziness. Episodes of hypotension or syncope are rare. No reports of priapism''' ** Although episodes of priapism were not reported in IU alprostadil trials, the man should be thoroughly educated about priapism and instructed on safe responses and maneuvers in a prolonged erection situation. * '''Contraindications to MUSE (3):''' *# '''Hypersensitivity''' *# '''Abnormal penile anatomy''' *# '''Conditions that increase the risk of priapism''' * '''For patients considering the use of IU alprostadil, an in-office test should be performed.''' ** Most studies proceeded with chronic treatment only in men who had erections firm enough for intercourse in response to in-office testing. The success rates among men who used the medication chronically, therefore, are relevant to responsive intra-office testing β not men with ED in general. ** IU alprostadil should not be prescribed until a man has undergone instruction in the method, an initial dose-titration in the office, and detailed counseling regarding possible adverse events and actions to take in response to potentially serious adverse events. * '''MUSE seems safe for female partners,''' producing only a 5.8% incidence of vaginal burning or itching, '''although it should be used with a condom for intercourse with a pregnant woman'''
Summary:
Please note that all contributions to UrologySchool.com may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
UrologySchool.com:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Page
Discussion
English
Views
Read
Edit
Edit source
View history
More
Search
Navigation
Main page
Clinical Tools
Guidelines
Chapters
Landmark Studies
Videos
Contribute
For Patients & Families
MediaWiki
Recent changes
Random page
Help about MediaWiki
Tools
What links here
Related changes
Special pages
Page information